Optimal Therapy for Primary and Metastatic Breast Cancer: Emerging Standards and New Approaches Oxford Overview: Understanding the Survival Benefit and the Role of Anthracycline-Based Treatment for Adjuvant Breast Cancer EXCERPTS Kathleen I. Pritchard, MD There is a difference, which is small but significant, between the AC regimens and the non-AC regimens, both for disease-free and overall survival. These curves are slightly apart, and they are significantly different. CMF =68.8% overall survival versus AC 71.5% overall survival at five years Doxorubicin-based studies, our CEF study, epirubicin-based studies, and the NSABP B-15 study, which is almost on the line in terms of effect on disease-free survival. This is another illustration of the fact that AC is not very different than CMF. There's the same curve for overall survival. Neoadjuvant Dose Intensive Chemotherapy in Locally Advanced Breast Cancer: Study Findings and Adverse Events EORTC - NCIC - SAKK LABC Study: Summary of Clinical Results Dose intensity ratio of EC to CEF. We got twice as much epirubicin and more than twice as much cyclophosphamide into the patients over the same time period as we would with CEF. In terms of the toxicities, CEF gave a bit more febrile neutropenia, but EC/G-CSF gave a bit more anemia, thrombocytopenia, and nausea. Unfortunately, the overall clinical results were not really different between the 2 arms. NEJM, 8/04 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.